Prosecution Insights
Last updated: August 06, 2026
Application No. 17/989,103

SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS

Final Rejection §102§103§112
Filed
Nov 17, 2022
Priority
Nov 18, 2021 — provisional 63/280,933
Examiner
MOORE, SUSANNA
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Enanta Pharmaceuticals Inc.
OA Round
6 (Final)
68%
Grant Probability
Favorable
7-8
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
850 granted / 1251 resolved
+7.9% vs TC avg
Strong +32% interview lift
Without
With
+31.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
60 currently pending
Career history
1317
Total Applications
across all art units

Statute-Specific Performance

§101
1.6%
-38.4% vs TC avg
§103
17.4%
-22.6% vs TC avg
§102
16.3%
-23.7% vs TC avg
§112
40.3%
+0.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1251 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This is a Final Office action. Election/Restrictions Group (I), without traverse, drawn to compounds of formula (I) and compositions thereof, embraced by claims 1-10 was elected by Applicant. Applicant has not pointed to any errors in the Examiner’s analysis of the classification of the different inventions. The requirement is still deemed proper and is therefore made FINAL. Applicant elected the following species: PNG media_image1.png 129 234 media_image1.png Greyscale , and indicated claims 1-7, 9 and 10 read on said species. The elected species was not found, and thus, the search was expanded. Claims 1-10, 12-15 and 18 are pending and claims 1-7, 9 and 10 are under examination. Claim 18 is a new claim Claims 8 and 18 are withdrawn based on the species election. Claims 12-15 are withdrawn based on the restriction requirement. Priority Applicant's claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) (PROVISIONAL) or 119(a) (FOREIGN) or under 35 U.S.C. 120 (CONT/CIP), 121(DIV), or 365(c) (WO) is acknowledged. Applicant still has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 119(e) as follows: The later-filed application must be an application for a patent application (the parent for an invention which is also disclosed in the prior application or provisional application). The disclosure of the invention in the parent application and in the later-filed application must be sufficient to comply with the requirements of the first paragraph of 35 U.S.C. 112. See Transco Products, Inc. v. Performance Contracting, Inc., 38 F.3d 551, 32 USPQ2d 1077 (Fed. Cir. 1994). The disclosure of the prior-filed application, Application No. 63280933, fails to provide adequate support or enablement in the manner provided by the first paragraph of 35 U.S.C. 112 for claim 9 of this application. There may be other omissions as well. Thus, the effective filing date of the present claim 9 remains the immediate filing date of November 17, 2022. Claim Objections Claims 3, 6 and 7 are objected to as being dependent upon a rejected base claim. Claim Rejections - 35 USC § 112 The rejection of claim 3 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for the phrase “R1 is derived from” is withdrawn based on the amendments. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claim Rejections - 35 USC § 102 The rejection of claims 1, 2 and 10 under 35 U.S.C. 102(a)(2) being anticipated by Wang et al. (US 20230103494) is withdrawn based on the 35 USC 102(b)(2)(C) statement that the reference is excluded. The rejection of claims 1, 2 and 10 under 35 U.S.C. 102(a)(2) being anticipated by Wang et al. (US 20220162231) is withdrawn based on the 35 USC 102(b)(2)(C) statement that the reference is excluded. Claim Rejections - 35 USC § 103 The rejection of claim 9 under AIA 35 U.S.C. 103(a) as being unpatentable over Luo et al. (WO 2023109926) is withdrawn based on the amendments. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action: (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a). Claims 1, 2, 4, 5, 9 and 10 are rejected under AIA 35 U.S.C. 103(a) as being unpatentable over Kulkarni et al. (Beilstein Journal of Organic Chemistry, 2010, 6, 876-879). The present application claims compounds of formula (IIa) and the following species: PNG media_image2.png 162 200 media_image2.png Greyscale PNG media_image3.png 88 330 media_image3.png Greyscale , see claim 9, page 13. All the compounds in the specification have the (R) configuration at the spiro carbon and the (S) configuration at the CN bond. The Kulkarni reference teaches the following species: PNG media_image4.png 367 325 media_image4.png Greyscale , see page 2. The main difference is the substitution at R1, methyl group versus Applicant’s ethyl, isopropyl, propyl, butyl, sec-butyl or isobutyl group. Since a methyl is considered a homolog of ethyl, isopropyl, propyl, butyl, sec-butyl or isobutyl groups these compounds are considered equivalent. The MPEP 2144.09 states “Compounds which are position isomers (compounds having the same radicals in physically different positions on the same nucleus) or homologs (compounds differing regularly by the successive addition of the same chemical group, e.g., by -CH2- groups) are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties. In re Wilder, 563 F.2d 457, 195 USPQ 426 (CCPA 1977). Adding the compound of formula (IIa) to a composition is obvious since most pharmaceuticals are sold as compositions. Therefore, said claims are obvious over Kulkarni et al. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUSANNA MOORE whose telephone number is (571)272-9046. The examiner can normally be reached on Monday - Friday, 10:00 am to 7:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached on 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see https://ppair-my.uspto.gov/pair/PrivatePair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUSANNA MOORE/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Show 8 earlier events
May 13, 2025
Response Filed
Jun 11, 2025
Final Rejection mailed — §102, §103, §112
Sep 24, 2025
Response after Non-Final Action
Nov 04, 2025
Request for Continued Examination
Nov 06, 2025
Response after Non-Final Action
Feb 19, 2026
Non-Final Rejection mailed — §102, §103, §112
Apr 30, 2026
Response Filed
Jul 27, 2026
Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12698306
BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD)
4y 0m to grant Granted Aug 04, 2026
Patent 12691084
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BONE DISEASES
4y 6m to grant Granted Jul 28, 2026
Patent 12692275
AROYL SUBSTITUTED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
3y 4m to grant Granted Jul 28, 2026
Patent 12686700
NEUROACTIVE STEROIDS SUBSTITUTED IN POSITION 10 WITH A CYCLIC GROUP FOR USE IN THE TREATMENT OF CNS DISORDERS
3y 5m to grant Granted Jul 21, 2026
Patent 12679851
METHYL-SUBSTITUTED BENZOBISOXAZOLE COMPOUND AND USE THEREOF
3y 7m to grant Granted Jul 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

7-8
Expected OA Rounds
68%
Grant Probability
99%
With Interview (+31.6%)
2y 10m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1251 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month